Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $195.5 million.

  • Arrowhead Pharmaceuticals' Total Current Liabilities rose 89.48% to $195.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 89.48%. This contributed to the annual value of $195.5 million for FY2025, which is 89.48% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Total Current Liabilities stood at $195.5 million for FY2025, which was up 89.48% from $103.2 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Total Current Liabilities ranged from a high of $195.5 million in FY2025 and a low of $103.2 million during FY2024.
  • For the 3-year period, Arrowhead Pharmaceuticals' Total Current Liabilities averaged around $134.7 million, with its median value being $105.5 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 260.20% in 2021, then decreased by 24.05% in 2023.
  • Arrowhead Pharmaceuticals' Total Current Liabilities (Yearly) stood at $146.5 million in 2021, then declined by 5.25% to $138.8 million in 2022, then declined by 24.05% to $105.5 million in 2023, then decreased by 2.17% to $103.2 million in 2024, then spiked by 89.48% to $195.5 million in 2025.